Daito Pharmaceutical Advances Share Buyback, Repurchases 208,800 Shares in March

The latest announcement is out from Daito Pharmaceutical Co., Ltd. ( (JP:4577) ).

Daito Pharmaceutical Co., Ltd. has repurchased 208,800 shares of its common stock on the Tokyo Stock Exchange between March 1 and March 31, 2026, at a total cost of 305,442,800 yen. The transaction was executed under the authority of its Articles of Incorporation and Japan’s Companies Act, reflecting an active capital allocation policy.

This buyback forms part of a broader share repurchase program approved by the board on October 10, 2025, which authorized purchases of up to 1,000,000 shares or 1.5 billion yen through May 22, 2026. As of March 31, 2026, the company has cumulatively repurchased 883,200 shares for 1,180,521,300 yen, signaling a substantial commitment to enhancing shareholder value and potentially supporting its stock price and capital efficiency metrics.

The most recent analyst rating on (JP:4577) stock is a Hold with a Yen1510.00 price target. To see the full list of analyst forecasts on Daito Pharmaceutical Co., Ltd. stock, see the JP:4577 Stock Forecast page.

More about Daito Pharmaceutical Co., Ltd.

Daito Pharmaceutical Co., Ltd., listed on the Prime Market of the Tokyo Stock Exchange under securities code 4577, operates in the pharmaceutical industry. The company focuses on the development and manufacture of pharmaceutical products, and its shares are actively traded on the Japanese equity market, making capital management measures such as share buybacks a relevant tool for shareholder returns.

Average Trading Volume: 92,007

Technical Sentiment Signal: Buy

Current Market Cap: Yen43.48B

For a thorough assessment of 4577 stock, go to TipRanks’ Stock Analysis page.